A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
Th1203 details |
| Primary information | |
|---|---|
| ID | 1812 |
| ThPP ID | Th1203 |
| Therapeutic Peptide/Protein Name | Peginterferon beta-1a |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ia |
| Molecular Weight | 20000 |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | Approximately 78 hours |
| Description | Peginterferon beta-1a is an interferon beta-1a to which a single, linear 20,000 dalton (Da) methoxy poly(ethyleneglycol)-O-2-methylpropionaldehyde molecule is covalently attached to the alpha amino group of the N-terminal amino acid residue. The interferon beta-1a portion is produced as a glycosylated protein using genetically-engineered Chinese hamster ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of the recombinant interferon beta-1a is identical to that of the human interferon beta counterpart. |
| Indication/Disease | For the treatment of patients with relapsing forms of multiple sclerosis. |
| Pharmacodynamics | There is no biochemical or physiologic effect known to relate directly to the clinical effect of PLEGRIDY. |
| Mechanism of Action | The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown. |
| Toxicity | NA |
| Metabolism | Clearance mechanisms for PLEGRIDY include catabolism and excretion. The major pathway of elimination is renal. |
| Absorption | The mean Cmax was 280 pg/mL, and the AUC over the 14 day dosing interval was 34.8 ng.hr/mL. |
| Volume of Distribution | The estimated volume of distribution was 481 liters |
| Clearance | The mean steady state clearance of PLEGRIDY is approximately 4.1 L/hr |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Theophylline, Zidovudine |
| Target | |
| Information of corresponding available drug in the market | |
| Brand Name | Plegridy |
| Company | Biogen Canada Inc |
| Brand Discription | The interferon beta-1a portion of PLEGRIDY is produced as a glycosylated protein using genetically-engineered Chinese hamster ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of the recombinant interferon beta-1a is identical to that of the human interferon beta counterpart. |
| Prescribed for | PLEGRIDY (peginterferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. |
| Chemical Name | Methoxy poly(ethyleneglycol)-O-2-methylpropionaldehyde |
| Formulation | Prefilled glass syringe containing 0.5 mL of a sterile solution in water for injection of 63, 94, or 125 micrograms of peginterferon beta-1a |
| Physcial Appearance | Sterile Solution |
| Route of Administration | Subcutaneous |
| Recommended Dosage | The recommended dosage of PLEGRIDY is 125 micrograms injected subcutaneously every 14 days. |
| Contraindication | PLEGRIDY is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of the formulation |
| Side Effects | Hepatic Injury; Depression and Suicide; Seizures; Anaphylaxis and Other Allergic Reactions; Injection Site Reactions; Congestive Heart Failure; Decreased Peripheral Blood Counts; Thrombotic Microangiopathy; Autoimmune Disorders. |
| Useful Link | http://www.rxlist.com/plegridy-drug/side-effects-interactions.htm |
| PubMed ID | 27835061, 27314959, 26039748, 25941954, 25846320, 25666445, 25432952, 24794721, 24556656 |
| 3-D Structure | N.A. |